Selskabets formål er at drive handelsvirksomhed med human medicin samt, efter bestyrlsens skøn, anden i forbindelse dermed stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 18.9 mio. | 2.3 mio. | 19.5 mio. | 3.4 mio. | 18 | |
CVR: 56750215
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Lundbeck Pharma A/S demonstrates a positive financial trajectory, with revenue increasing from 15,968,000 DKK in 2023 to 18,887,000 DKK in 2025, reflecting a steady growth trend. Profitability has also improved, rising from 991,000 DKK in 2023 to 2,291,000 DKK in 2025, indicating enhanced operational efficiency and margins. However, equity has slightly declined from 3,484,000 DKK in 2024 to 3,378,000 DKK in 2025, which may raise concerns regarding financial stability. Positioned within the pharmaceutical wholesale industry, Lundbeck Pharma's growth and profitability suggest a solid standing, though ongoing monitoring of equity and market conditions is advisable.
AI-generated summary
Companies in the same industry and area
companydata.dk